First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

Summary

This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

Timeline

Start

2022-08-30

Primary completion

2024-10-31

Completion

2024-10-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor's Research and Development strategy adjustment”

Drugs

Indications